Hyperkalemia treatment

Reading File

Finding Sources

Searching PubMed

hyperkalemia treatment management

Reading File

Finding Sources

Reading File

Loading Image

Here is a comprehensive overview of hyperkalemia treatment, organized by urgency.

Hyperkalemia Treatment

Fig. 10.3 — Approach to treatment of hyperkalemia (National Kidney Foundation Primer on Kidney Diseases, 8e)

ECG changes (peaked T waves → widened QRS → loss of P wave → sine wave) at any K⁺ level constitute an emergency.

IV Calcium — does NOT lower potassium; directly antagonizes myocardial membrane excitability.

Calcium gluconate: 10 mL of 10% solution IV over 1–3 min (preferred peripherally; safer if extravasation occurs)
Calcium chloride: 10 mL of 10% solution over 10 min — more elemental calcium per ampule but causes skin necrosis if it infiltrates; use only via central line
Effect is almost immediate; if no ECG improvement in 3–5 min, repeat the dose
⚠️ Use with caution in patients on digoxin (may precipitate toxicity)

These measures reduce plasma K⁺ temporarily (1–4 hours); they do not remove K⁺ from the body.

Agent	Dose	Onset	Notes
Regular insulin + dextrose	10 U IV + 50 mL D50W bolus, then D5W at 100 mL/hr	15 min	Fastest transcellular shift; monitor glucose closely — hypoglycemia common, especially in renal failure. If glucose >300 mg/dL, may omit dextrose
Nebulized albuterol	20 mg in 4 mL nebulized over 10 min	30 min	Additive to insulin; ~30% of patients are resistant. IV albuterol (0.5 mg) available in Europe gives equivalent effect
Sodium bicarbonate	50–100 mEq IV over 10–20 min	Variable	Useful only if severe metabolic acidosis (HCO₃⁻ <10 mmol/L); does NOT enhance insulin/albuterol effect; limited benefit in anuric patients

Loop and thiazide diuretics are effective when adequate renal function is present.

Agent	Dose	Time of Onset	Notes
Sodium polystyrene sulfonate (SPS / Kayexalate)	15–50 g PO in sorbitol; or 50 g retention enema	Hours to days	Rectal route faster; rarely causes colonic necrosis (FDA black-box warning when combined with sorbitol); not approved for chronic use
Patiromer (Veltassa)	8.4 g PO once daily	~7 hours	Exchanges Ca²⁺ for K⁺ in colon; approved for chronic management; separate from other oral drugs by ≥3 h; monitor Mg²⁺
Sodium zirconium cyclosilicate (Lokelma)	Standard protocol	~1 hour	Binds K⁺ in exchange for H⁺/Na⁺ throughout GI tract; 9× higher binding capacity than SPS per gram; approved for chronic management

Most effective method; indicated in anuric patients (severe AKI or ESKD) or when conservative measures fail.
Rarely initiates fast enough to preclude the above emergency measures.

For biochemical hyperkalemia without ECG changes:

Dietary K⁺ restriction — avoid high-K⁺ foods, salt substitutes
Discontinue offending drugs — ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin, TMP-SMX
Loop diuretics — especially if eGFR <30 mL/min
Oral sodium bicarbonate — for concomitant metabolic acidosis
Fludrocortisone — if mineralocorticoid deficiency (hypoaldosteronism, e.g., Type IV RTA)
Long-term K⁺ binders (patiromer or ZS-9) — to facilitate continued use of RAASi in CKD/heart failure

Calcium — membrane stabilizer only; acts in seconds; repeat if no response in 3–5 min
Insulin ± albuterol — fastest intracellular shift; always cover with dextrose
Never give dextrose alone without insulin in insulin-deficient patients (can paradoxically worsen hyperkalemia via osmotic shift)
Bicarbonate — limited acute role; reserve for severe acidosis (HCO₃⁻ <10)
Dialysis — definitive therapy in renal failure
Newer binders (patiromer, ZS-9) are preferred over Kayexalate for chronic management due to better safety profiles

— National Kidney Foundation Primer on Kidney Diseases, 8e | Schwartz's Principles of Surgery, 11e | Sabiston Textbook of Surgery

This is a shared conversation. Sign in to Orris to start your own chat.